Related Experiment Video

Updated: Dec 3, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.8K

Recent trends in renal denervation devices for resistant hypertension treatment

Sumeeyae Haribabu1,2, Faisal Sharif1,2,3,4,5, Haroon Zafar6,7,8

  • 1Cardiovascular Research & Innovation Centre, National University of Ireland Galway, Galway, Ireland.

Irish Journal of Medical Science
|October 28, 2020
PubMed

Insights

Renal denervation (RDN) offers a promising neuromodulation treatment for hypertension. Despite past setbacks, recent trials show RDN is a viable alternative, with various devices available and under development.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Medical Devices

Background:

  • Hypertension is a major risk factor for cardiovascular disease and mortality.
  • Global hypertension prevalence exceeds 1.13 billion, with suboptimal control.
  • Renal denervation (RDN) was developed for resistant hypertension and other conditions.

Purpose of the Study:

  • To review current state-of-the-art Renal Denervation (RDN) devices.
  • To provide an in-depth review of future RDN devices.
  • To discuss the resurgence of RDN as a treatment alternative.

Main Methods:

  • Review of current and emerging Renal Denervation (RDN) devices.
  • Analysis of RDN's role in treating hypertension and related conditions.
  • Examination of ablation techniques including radiofrequency and ultrasound energy.

Main Results:

  • Initial RDN trials for resistant hypertension did not meet efficacy endpoints.
  • Recent successful trials indicate RDN's renewed potential as a treatment.
  • A comprehensive list of current devices (Symplicity Flex, Spyral, Vessix, EnligHTN, Iberis, TIVUS, Paradise) is presented.

Conclusions:

  • Renal denervation (RDN) is re-emerging as a significant treatment option for hypertension.
  • Future RDN devices show continued innovation in neuromodulation therapy.
  • RDN holds potential beyond resistant hypertension, including heart failure, diabetes, and renal failure.

Keywords:
Medical devicesRenal denervationResistant hypertensionSympathetic nerves

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

529
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.3K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
705
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
308
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
115
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
342
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.8K